Table 3.
Median survival, in months, according to prognostic factors
| Treatment | Prognostic Factor (CI*) | ||
|---|---|---|---|
| Patient Age | |||
| <40 | 40–50 | >50 | |
| Temozolomide | |||
| Number of patients | 30 | 20 | 10 |
| MST (CI) | NA | 31 (26–NA) | 16 (12–NA) |
| PCV | |||
| Number of patients | 32 | 8 | 9 |
| MST (CI) | NA (56–NA) | NA (61–NA) | 28 (25–NA) |
| Total | |||
| Number of patients | 62 | 28 | 19 |
| MST (CI) | NA (58–NA) | 61 (30–NA) | 25 (15–NA) |
| KPS | ||
|---|---|---|
| <80 | ⩾80 | |
| Temozolomide | ||
| Number of patients | 9 | 51 |
| MST (CI) | 18 (10–NA) | NA |
| PCV | ||
| Number of patients | 5 | 44 |
| MST (CI) | 17 (15–NA) | NA (61–NA) |
| Total | ||
| Number of patients | 14 | 95 |
| MST (CI) | 17 (15–26) | NA |
| Enhancement | ||
|---|---|---|
| Absent | Present | |
| Temozolomide | ||
| Number of patients | 28 | 32 |
| MST (CI) | NA | 31 (24–NA) |
| PCV | ||
| Number of patients | 35 | 14 |
| MST (CI) | NA | 30 (33–NA) |
| Total | ||
| Number of patients | 63 | 46 |
| MST (CI) | NA | 30 (26–61) |
| Extent of surgery | |||
|---|---|---|---|
| Biopsy | Subtotal | Total | |
| Temozolomide | |||
| Number of patients | 8 | 30 | 22 |
| MST (CI) | 14 (11–NA) | 42 (26–NA) | NA |
| PCV | |||
| Number of patients | 9 | 18 | 22 |
| MST (CI) | 39 (26–NA) | 60 (30–NA) | NA |
| Total | |||
| Number of patients | 17 | 48 | 44 |
| MST (CI) | 26 (14–NA) | 56 (30–NA) | NA |
Abbreviations: CI, 95% confidence interval; MST, median survival time; NA, not achieved; PCV, procarbazine, CCNU, and vincristine.